Nyrada, Inc. · ASX:NYR
Nyrada — Non-Deal Roadshow (March 2022)
22 slides from Nyrada's roadshow presentation, Mar 30, 2022
Slide 1: Updated Nyrada Investor Roadshow Presentation
30 March 2022 Sydney, Australia For personal use only Updated Nyrada Investor Roadshow Presentation Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation ahead of a domestic investor roadshow led by Nyrada CEO, James Bonnar, which is taking
Slide 2: Forward-Looking Statements
Forward-Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Investor Presentation
For personal use only Investor Presentation March & April 2022│Sydney NSW NYRADA INC (ASX:NYR) Authorised by Mr. John Moore, Non-Executive 1 Chairman, on behalf of the Board. INVESTOR PRESENTATION
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should Although the Company believes that the expectations reflected in the forward-looking not be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 5: Company Overview
Company Overview For personal use only • Two lead drug development programs with significant therapeutic and commercial potential: ‐ Cholesterol-Lowering Program ‐ Brain Injury Program • Preclinical studies delivering superior results • Collaborations with world leading institutions, Walter Reed Arm
Slide 6: Nyrada Leadership Team
Nyrada Leadership Team For personal use only • Nyrada operates under the direction of a board of international calibre • Strong track record in finding and Mr John Moore Dr Ian Dixon Christopher Cox Mr Peter Marks realising the value of Non-Executive Chairman Non-Executive Director Non-Executive Dir
Slide 7: Scientific Advisory Board
Scientific Advisory Board For personal use only Professor Gary Housley Professor David Burke Professor Gilles Lambert Professor Junichi Dr. Jim Palmer Chair, M.Sc Ph.D MD, DSc, AC Ph.D Nabekura, Ph.D Ph.D Chair in Physiology (UNSW) Professor of Neurology Professor in Cell Biology at Professor of Phy
Slide 8: Vision & Strategy
Vision & Strategy For personal use only • To improve lives and offer hope through innovation • Deliver novel treatments for diseases where: ‐ There is unmet clinical need; or ‐ Current treatments are suboptimal Our strategy is to advance highly optimised drug candidates towards a key value inflectio
Slide 9: Cholesterol-Lowering Program
For personal use only Cholesterol-Lowering Program ASX:NYR NYRADA INC (ASX:NYR) 7 INVESTOR PRESENTATION
Slide 10: High LDL Cholesterol and Cardiovascular Disease (CVD)
High LDL Cholesterol and Cardiovascular Disease (CVD) Problem and key statistics For personal use only Statins are suboptimal for High LDL Healthcare costs cholesterol a CVD responsible for CVD 70% of patients and often leading cause of for 1 in 4 deaths ~US$363B/year poorly tolerated CVD (US)1 • St
Slide 11: Nyrada's Cholesterol-Lowering Program
Nyrada’s Cholesterol-Lowering Program For personal use only • We are developing an oral PCSK9 inhibitor drug (taken as a pill) for the treatment of high LDL (bad) cholesterol levels in patients at risk of cardiovascular disease • Nyrada’s drug would replace expensive and inconvenient injectable PCSK
Slide 12: Program Milestones
Program Milestones For personal use only 2H CY2020 1H CY2021 2H CY2021 UPCOMING JUL 2021 DEC 2021 DEC 2020 MAY 2021 CY 2022 US Patent & Charles River NYX-PCSK9i Medicinal Trademark Office Laboratories Charles River Laboratories to conduct shows 57% chemistry program issue first patent for appointed
Slide 13: Brain Injury Program
For personal use only Brain Injury Program ASX:NYR NYRADA INC (ASX:NYR) 11 INVESTOR PRESENTATION
Slide 14: Global Market with Large Unmet Need - Brain Injury After TBI or Stroke
Global Market with Large Unmet Need - Brain Injury After TBI or Stroke For personal use only Nyrada is developing a neuroprotectant drug to reduce the impact of secondary brain injury in patients following a stroke or traumatic brain injury (TBI), which can occur following a motor vehicle accident,
Slide 15: Reducing Secondary Brain Injury After TBI or Stroke
Reducing Secondary Brain Injury After TBI or Stroke First-ever drug to improve survivability and patient quality of life For personal use only • Treatment for secondary brain injury following TBI or Stroke • Administered intravenously (TBI and Stroke) or intranasally Primary Secondary Disability Inj
Slide 16: Program Milestones
Program Milestones For personal use only 2H CY2020 CY2021 CY2022 FEB 2021 MAR 2022 • Collaboration secured with • New lead drug candidate NYR-BI02 WRAIR and UNSW Sydney selected for Phase I study JULY 2020 JUN 2021 UPCOMING • Pilot study evaluating the intranasal route • New, more potent analogue of
Slide 17: For personal use only
For personal use only Corporate Update ASX:NYR NYRADA INC (ASX:NYR) 15 INVESTOR PRESENTATION
Slide 18: FY2021 Financial Summary
FY2021 Financial Summary For personal use only Highlights • Cash position as at 31 December 2021 was $11.1M • R&D Tax Incentive refund of $2.3M relating to the accrued FY2021 refund of $1.3M and received FY2020 refund of $1.0M • R&D Tax Incentive refund of $1.3M received in January 2022, further boo
Slide 19: Strong Intellectual Property Position
Strong Intellectual Property Position For personal use only • US Patent granted for Nyrada’s PCSK9 inhibitor technology (expiry date 16 March 2038) • Provides composition of matter protection • Corresponding European patent is in the final stages of examination • PCT application filed in December 20
Slide 20: Key Metrics & Timing of Phase I Studies
Key Metrics & Timing of Phase I Studies For personal use only Key Metrics Pathway to Phase I Studies Market capitalisation $32.7M Expected to Commence* (as at 29 March 2022) Share price Cholesterol-Lowering Program 2H CY2022 $0.21 (as at 29 March 2022) Brain Injury Program 2H CY2022 CDIs free float
Slide 21: Questions?
For personal use only Questions? Brain Injury Solution Cholesterol-Lowering Animation Animation @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 19 INVESTOR PRESENTATION
Slide 22: www.nyrada.com
For personal use only www.nyrada.com NYRADA INC (ASX:NYR) 20 INVESTOR PRESENTATION